Impact of the FIGO2023 staging system on endometrial cancer in Japan: differences between next-generation sequencing and simplified surrogate marker analysis
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Ryoken Nara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Staging, High-Throughput Nucleotide Sequencing, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Background
The International Federation of Gynecology and Obstetrics (FIGO) revised the staging system of endometrial cancer in 2023. In this study, we aimed to determine stage transitions and prognosis of endometrial cancer using FIGO2008, FIGO2023 without molecular classification (FIGO2023), and FIGO2023 with molecular classification (FIGO2023m).
Methods
Eighty-three patients diagnosed with endometrial cancer who underwent surgery and next-generation sequencing (NGS) molecular profiling as part of the Project HOPE cohort study were enrolled. Each case was staged according to the FIGO2008 and FIGO2023 criteria, and we evaluated changes in stage and disease-specific survival (DSS). Molecular classification based on NGS was performed to evaluate FIGO2023m, and the concordance rate with immunohistochemical marker analysis was assessed.
Results
Transitioning from FIGO2008 to FIGO2023 resulted in the restaging of 18 cases. Conversely, transitioning from FIGO2008 to FIGO2023m led to the restaging of 15 cases. The concordance rate between FIGO2023 and FIGO2023m staging was 96.4%. With FIGO2023m, the 5-year DSS was 97.6% for stage I (95% confidence interval [CI] 83.9–99.7), 83.3% for stage II (95% CI 56.8–94.3), 100% for stage III (95% CI NA), and 25.0% for stage IV (95% CI 0.9–66.5). Discrepancies in disease staging due to discordance between simplified surrogate marker analysis and NGS evaluation occurred in two cases.
Conclusions
The revision of the staging system from FIGO2008 to FIGO2023 and FIGO2023m resulted in the restaging of several cases, with significant changes between stages I and II.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan.
- Department of Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan.
- Cancer Multiomics Division, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan.
- Cancer Diagnostics Research Division, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan.
- Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka 411-8777, Japan.
ORCID-Profile: Nobutaka Takahashi, Yasuyuki Hirashima
Zitieren
APA
Nara, R., Furusawa, A., Hiraki, T., Takahashi, N., Hatakeyama, K., Urakami, K., Hirashima, Y., & Yamaguchi, K. (2024). Impact of the FIGO2023 staging system on endometrial cancer in Japan: differences between next-generation sequencing and simplified surrogate marker analysis. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae114
Vancouver
Nara R, Furusawa A, Hiraki T, Takahashi N, Hatakeyama K, Urakami K, et al. Impact of the FIGO2023 staging system on endometrial cancer in Japan: differences between next-generation sequencing and simplified surrogate marker analysis. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae114
BibTeX
@article{Nara2024,
author = {Nara, Ryoken and Furusawa, Akiko and Hiraki, Tsubasa and Takahashi, Nobutaka and Hatakeyama, Keiichi and Urakami, Kenichi and Hirashima, Yasuyuki and Yamaguchi, Ken},
title = {Impact of the FIGO2023 staging system on endometrial cancer in Japan: differences between next-generation sequencing and simplified surrogate marker analysis},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae114}
}
EUVIMED